Endevica Bio Overview
- Founded
-
2009

- Status
-
Private
- Employees
-
3

- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$5.02M
- Investors
-
5
Endevica Bio General Information
Description
Developer of therapeutic drugs intended to treat cachexia due to cancer and other chronic conditions. The company's drugs are melanocortin-based peptide drugs for treating cardiovascular problems which are free from any adverse cardiovascular side effects, enabling healthcare practitioners to use these drugs for proper treatment of cancer and other chronic diseases.
Contact Information
Website
www.endevicabio.com
Formerly Known As
Tensive Controls
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 1601 South Providence Road
- Columbia, MO 65211
- United States
+1 (573) 000-0000
Endevica Bio Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
5. Grant | 01-Jun-2017 | $5.02M | 00.000 | Completed | Generating Revenue | |
4. Later Stage VC (Series A) | 01-Jun-2016 | 00.000 | 00.000 | Completed | Generating Revenue | |
3. Grant | 01-Jan-2014 | 0000 | Completed | Generating Revenue | ||
2. Grant | 01-Jan-2012 | $1.75M | Completed | Startup | ||
1. Early Stage VC | Completed | Startup |
Endevica Bio Patents
Endevica Bio Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20170247414-A1 | Anti-microbial peptides | Granted | 19-Sep-2014 | 00000000 | 0 |
EP-3194422-A4 | Anti-microbial peptides | Granted | 19-Sep-2014 | 00000000 | |
EP-3194422-A1 | Anti-microbial peptides | Granted | 19-Sep-2014 | 00000000 | |
EP-3194422-B1 | Anti-microbial peptides | Active | 19-Sep-2014 | 00000000 | |
US-20200109171-A1 | Anti-microbial peptides | Granted | 19-Sep-2014 | C07K7/08 | 0 |
Endevica Bio Executive Team (6)
Endevica Bio Board Members (2)
Name | Representing | Role | Since |
---|---|---|---|
Daniel Marks MD | Endevica Bio | Chief Medical Officer & Board Member | 000 0000 |
Russell Potterfield | Endevica Bio | Co-Chief Executive Officer & Executive Chairman | 000 0000 |
Endevica Bio Signals
Endevica Bio Investors (5)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Centennial Investors | Angel Group | Minority | 000 0000 | 000000 0 | |
United States Department of Agriculture | Government | 000 0000 | 000000 0 | ||
National Cancer Institute | Government | 000 0000 | 000000 0 | ||
U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 | ||
Missouri Technology Corporation | Venture Capital | Minority | 000 0000 | 000000 0 |